about
Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentExpression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand.Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateInhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individualsSafety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responsesCD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection.Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneSafety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection.Designing the epitope flanking regions for optimal generation of CTL epitopes.Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection.Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene.Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons.Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial.S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial.Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III TrialErratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionDiscordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementiaHIV-Associated Wasting in the Era of Highly Active Antiretroviral Therapy: A Syndrome of Residual HIV Infection in Monocytes and Macrophages?Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected AdultsSelective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV InfectionA phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative ThaisVaricella immunity: persistent serologic non-response to immunizationGeneration and Expansion of HIV-1 CD4+ Antigen-Specific T Cell Lines
P50
Q33310152-19B591ED-C32E-41A8-85D9-279F4C246135Q33314468-60E9ABE0-EFF1-4E12-9A00-96E9D2A4BC2EQ33749950-23FCB2C9-34E8-4C53-BC10-BC0E765FBD1DQ33849085-AEC487B3-0F6D-40BA-94C9-A7E6FC6EA661Q34218500-48828E52-3F68-446B-9478-9246CDB3F921Q34335632-5511D13F-B2F7-4D3C-B526-7E98765B18EEQ34374375-50212B47-B2D8-41E5-B57B-8BADE5B1D5F3Q34414726-2D5573AB-AFC9-4832-8AD9-01ACE8A32E7DQ34508049-0D011FBC-C30A-4035-ABEA-DA15EC757EA0Q35064258-85544C55-37DB-41DB-B804-25139001665EQ35673120-E208B961-23ED-45CA-BF77-75B9DF6016E3Q35883032-80CCB3BD-0C9D-46C2-9681-2264D8D9FA10Q36046570-B98BB3AB-F842-48AA-A40B-00CD877A8336Q36931790-1A7A213F-31A0-43F5-AF7B-67A6E5E582B5Q39358702-524B7B73-48EF-41D8-9DE7-27511734B706Q39726192-21FA40D7-BE7F-4C94-B284-C0B2A6F8CF9BQ40057846-F5D37D1E-9526-46AC-A4F8-D40BAA3C6033Q42145907-D267184B-C65F-4CF9-BA6A-4DD54A23EBB1Q42220600-0FF20482-9D57-45FE-8FC2-1A01B008F827Q43726131-1DF09F68-B252-48E6-BAE9-344D67AFC1E7Q44767986-C9C725E1-E564-44E5-A26E-BFAC3561CCCBQ45760093-4E15C766-4B16-4846-AD5E-B5A7298B75DEQ46984982-1D791B1D-9935-4E73-A0F1-0C1DF6DEE78BQ46990633-60DFA66D-1422-41A5-84A5-F0DCA3361F38Q47381499-ECC9C5CA-25C8-4905-A29E-14715BF9D46EQ47604388-FB17989F-89BD-48D6-A460-411DCC993295Q47773263-DAB62514-4852-4026-9201-E2F0BD7CC8DDQ49482714-D0F1D6B8-7C6D-47AA-80F9-6A4C67A590CAQ55496825-9BB1D26A-8404-42FA-A21E-4FAC35C33843Q55619268-D3A6F838-C46D-4061-A35E-0B9AF2B1EC20Q55626604-1FB8BF00-BC04-4063-8266-FFC880EFEDEEQ58834243-2C22071F-2F37-439C-BDCA-C3393663C287Q59309137-0D292C49-81C1-498F-B0D0-6BA3EF864CB1Q59309181-4178006F-F932-409F-A86A-27D222969897Q59309182-AF1B3C24-E135-46B2-8EEF-F3238A0F90A6Q59309186-D75001CF-5908-4A74-BC6C-CB8600FBAD4FQ59309189-2EB88D51-734A-4CC4-88C2-DC2E1EC0BAFBQ59309192-234BF9E6-7FD6-4820-A567-9F71F2564D97Q59309194-863F182F-F7E4-4D71-BF73-86C4F4C2007BQ59309208-0A0656E5-7B5F-408D-9B13-882AB3A4C484
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Ratto-Kim
@ast
Silvia Ratto-Kim
@en
Silvia Ratto-Kim
@es
Silvia Ratto-Kim
@nl
Silvia Ratto-Kim
@sl
type
label
Silvia Ratto-Kim
@ast
Silvia Ratto-Kim
@en
Silvia Ratto-Kim
@es
Silvia Ratto-Kim
@nl
Silvia Ratto-Kim
@sl
prefLabel
Silvia Ratto-Kim
@ast
Silvia Ratto-Kim
@en
Silvia Ratto-Kim
@es
Silvia Ratto-Kim
@nl
Silvia Ratto-Kim
@sl
P106
P21
P31
P496
0000-0003-2025-6399